Sectors & IndustriesHealthcareMedical Instruments & Supplies

Best Medical Stocks to Buy Now (2025)

Top medical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best medical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical stocks to buy right now are:

Embecta (NASDAQ:EMBC) is the #1 top medical stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: A.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 5 points higher than the medical industry average of 30.

EMBC passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -6.43% over the past year, overperforming other medical stocks by 33 percentage points.

Embecta has an average 1 year price target of $18.50, an upside of 28.38% from Embecta's current stock price of $14.41.

Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Nephros (NASDAQ:NEPH) is the #2 top medical stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Nephros (NASDAQ:NEPH) is: Value: C, Growth: C, Momentum: B, Sentiment: A, Safety: C, Financials: B, and AI: C.

Nephros (NASDAQ:NEPH) has a Due Diligence Score of 42, which is 12 points higher than the medical industry average of 30.

NEPH passed 13 out of 33 due diligence checks and has strong fundamentals. Nephros has seen its stock return 171.17% over the past year, overperforming other medical stocks by 210 percentage points.

Nephros has an average 1 year price target of $6.00, an upside of 35.75% from Nephros's current stock price of $4.42.

Nephros stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Nephros, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Infusystem Holdings (NYSEMKT:INFU) is the #3 top medical stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 42, which is 12 points higher than the medical industry average of 30.

INFU passed 13 out of 33 due diligence checks and has strong fundamentals. Infusystem Holdings has seen its stock return 13.77% over the past year, overperforming other medical stocks by 53 percentage points.

Infusystem Holdings has an average 1 year price target of $14.50, an upside of 42.72% from Infusystem Holdings's current stock price of $10.16.

Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 10 medical stocks that have issued dividends in the past year, the 3 medical stocks with the highest dividend yields are:

Dentsply Sirona (NASDAQ:XRAY) has an annual dividend yield of 4.38%, which is 2 percentage points higher than the medical industry average of 2.04%. Dentsply Sirona's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Dentsply Sirona's dividend has shown consistent growth over the last 10 years.

Dentsply Sirona's dividend payout ratio of -14.6% indicates that its high dividend yield might not be sustainable for the long-term.

Embecta (NASDAQ:EMBC) has an annual dividend yield of 4.16%, which is 2 percentage points higher than the medical industry average of 2.04%.

Embecta's dividend payout ratio of 66.7% indicates that its high dividend yield is sustainable for the long-term.

Baxter International (NYSE:BAX) has an annual dividend yield of 3.64%, which is 2 percentage points higher than the medical industry average of 2.04%. Baxter International's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Baxter International's dividend has shown consistent growth over the last 10 years.

Baxter International's dividend payout ratio of -103% indicates that its dividend yield might not be sustainable for the long-term.

Medical stocks were down -1.33% in the last day, and up 2.1% over the last week.

We couldn't find a catalyst for why medical stocks are down.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued medical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 36 points higher than the medical industry average of 21. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -6.43% in the past year. It has overperformed other stocks in the medical industry by 33 percentage points.

Harvard Bioscience (NASDAQ:HBIO) is the second most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harvard Bioscience has a valuation score of 14, which is -7 points higher than the medical industry average of 21. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates HBIO a Valuation Rating of "B".

Harvard Bioscience's stock has dropped -73.18% in the past year. It has underperformed other stocks in the medical industry by -34 percentage points.

Haemonetics (NYSE:HAE) is the third most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Haemonetics has a valuation score of 29, which is 8 points higher than the medical industry average of 21. It passed 2 out of 7 valuation due diligence checks.

Haemonetics's stock has dropped -19.47% in the past year. It has overperformed other stocks in the medical industry by 20 percentage points.

48.72% of medical stocks rated by analysts are a buy right now. On average, analysts expect medical stocks to rise by 18.63% over the next year.

8.89% of medical stocks have a Zen Rating of A (Strong Buy), 13.33% of medical stocks are rated B (Buy), 57.78% are rated C (Hold), 15.56% are rated D (Sell), and 4.44% are rated F (Strong Sell).